Reaxys® Medicinal Chemistry Provided as Part of Elsevier’s Suite of Life Science Solutions Delivers High Quality Content to Improve Drug Discovery and Development
Comprehensive, referenced and well-structured data allows users to increase speed and accuracy of decision making in the drug development process
Amsterdam, February 4, 2013 – Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of Reaxys Medicinal Chemistry. It offers medicinal chemists access to comprehensive, referenced and well-structured data to enhance the compound selection process across discovery and pre-clinical stages in drug research and development. Reaxys Medicinal Chemistry will significantly improve the efficiency and productivity of researchers engaged in the process of designing compounds and optimizing their compatibility with one or more targets in order to successfully treat a disease.
Dr. Juergen Swienty-Busch, Product Lead for the Reaxys suite at Elsevier said, “The greatest challenge of medicinal chemistry is to reduce the number of drug candidates that fail in late stages, significantly increasing the cost of bringing a drug to market. The well-known mantra ‘fail early, fail cheap’ is now central to the drug discovery process, with much of the responsibility borne by medicinal chemists.”
Medicinal chemists develop strategies to find new drugs and to improve not only the efficacy of compounds but also selectivity, ADME properties and safety end-points. To support these strategies, medicinal chemists need to have access to up to date, well organized and high quality experimental data on druggable targets, pharmacological effects, biological data points, and ADME properties associated with chemical compounds.
Reaxys Medicinal Chemistry sources its data from a vast repository of peer-reviewed journal articles, patents and regulatory information, encompassing millions of compounds and associated biological data linked to thousands of druggable proteins. It brings this information together into a single, easily searchable solution that gives pharmaceutical companies access to comparative data.
Reaxys Medicinal Chemistry can be used in conjunction with Elsevier’s suite of life science products; including Reaxys, the leading chemistry discovery engine, and PharmaPendium, which focuses on regulatory approvals and drug safety. This solution effectively brings together lead identification, confirmation and drug repurposing.
# # #
Reaxys® is a workflow solution for research chemists. Offering a wealth of experimentally validated information, Reaxys® combines reaction and substance data in organic, organometallic, inorganic and physical chemistry with synthesis planning. Researchers can get the information they need in a single overview, from source publications carefully selected for their importance and relevance to research chemists. Elsevier continues to engage with the chemistry community to ensure that Reaxys® continues to reflect how chemists think and work. For more information please visit https://www.reaxys.com/info/.
Reaxys and the Reaxys trademark are owned and protected by Reed Elsevier Properties SA and used under license.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries. www.elsevier.com
Director, Corporate Relations
+31 20 485 27 36